Literature DB >> 15044962

Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.

Kyung-Sun Hwang1, Won-Kyung Cho, Jinsang Yoo, Young Rim Seong, Bum-Kyeng Kim, Samyong Kim, Dong-Soo Im.   

Abstract

We report here that gene transfer using recombinant adenoviruses encoding interleukin (IL)-18 mutants induces potent antitumor activity in vivo. The precursor form of IL-18 (ProIL-18) is processed by caspase-1 to produce bioactive IL-18, but its cleavage by caspase-3 (CPP32) produces an inactive form. To prepare IL-18 molecules with an effective antitumor activity, a murine IL-18 mutant with the signal sequence of murine granulocyte-macrophage (GM)- colony stimulating factor (CSF) at the 5'-end of mature IL-18 cDNA (GMmIL-18) and human IL-18 mutant with the prepro leader sequence of trypsin (PPT), which is not cleaved by caspase-3 (PPThIL-18CPP32-), respectively, were constructed. Adenovirus vectors carrying GMmIL-18 or PPThIL-18CPP32- produced bioactive IL-18. Ad.GMmIL-18 had a more potent antitumor effect than Ad.mProIL-18 encoding immature IL-18 in renal cell adenocarcinoma (Renca) tumor-bearing mice. Tumor-specific cytotoxic T lymphocytes, the induction of Th1 cytokines, and an augmented natural killer (NK) cell activity were detected in Renca tumor-bearing mice treated with Ad.GMmIL-18. An immunohistological analysis revealed that CD4+ and CD8+ T cells abundantly infiltrated into tumors of mice treated with Ad.GMmIL-18. Huh-7 human hepatoma tumor growth in nude mice with a defect of T cell function was significantly inhibited by Ad.PPThIL-18CPP32- compared with Ad.hProIL-18 encoding immature IL-18. Nude mice treated with Ad.PPThIL-18CPP32- contained NK cells with increased cytotoxicity. The results suggest that the release of mature IL-18 in tumors is required for achieving an antitumor effect including tumor-specific cellular immunity and augmented NK cell-mediated cytotoxicity. These optimally designed IL-18 mutants could be useful for improving the antitumor effectiveness of wild-type IL-18. Copyright 2004 Nature Publishing Group

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15044962     DOI: 10.1038/sj.cgt.7700711

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  5 in total

1.  Semliki forest virus expressing interleukin-12 induces antiviral and antitumoral responses in woodchucks with chronic viral hepatitis and hepatocellular carcinoma.

Authors:  Juan R Rodriguez-Madoz; Katherine H Liu; Jose I Quetglas; Marta Ruiz-Guillen; Itziar Otano; Julien Crettaz; Scott D Butler; Christine A Bellezza; Nathan L Dykes; Bud C Tennant; Jesus Prieto; Gloria González-Aseguinolaza; Cristian Smerdou; Stephan Menne
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

2.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

3.  Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.

Authors:  Kyung-Sun Hwang; Won-Kyung Cho; Jinsang Yoo; Hwan-Jung Yun; Samyong Kim; Dong-Soo Im
Journal:  BMC Cancer       Date:  2005-05-24       Impact factor: 4.430

Review 4.  Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.

Authors:  Matthew Bell; Stephen Gottschalk
Journal:  Front Immunol       Date:  2021-06-04       Impact factor: 7.561

5.  Intracellular distributing and interferon-γ secretion of human interleukin-18 in BxPC-3 cells.

Authors:  Jin Yang; Linlin Chen; Bin Xu; Jian Xu; Jinquan Sun; Wen Shen; Ting Zhang
Journal:  Int J Med Sci       Date:  2014-01-07       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.